Study of a new combination inhaler for asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had asthma for at least 6 months.
- You currently use a rescue inhaler (like albuterol) when your asthma flares up, with or without a daily controller medication.
- You are 12 years old or older.
- You have not had a life-threatening asthma attack that needed a breathing tube or caused serious problems.
- You haven't had a respiratory infection (like a cold or flu) in the last 2 weeks, or COVID-19 in the last 6 weeks.
- You do not smoke and have not smoked heavily in the past (less than 10 pack-years total), and you don't use vaping, e-cigarettes, or marijuana.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
This study tests a new medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with their current inhalers. It is for adults who have had asthma for at least a year, have had recent flare-ups needing steroids, and are not taking other biologic treatments.
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study tests a new combination inhaler (budesonide/albuterol) against another asthma inhaler in adults whose asthma is not well controlled on their current medications. It aims to see if the new inhaler can reduce serious asthma attacks and improve symptoms.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.